Yazar "Tikiz H." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    The effect of anti-tumor necrosis factor (TNF)-alpha therapy with etanercept on endothelial functions in patients with rheumatoid arthritis [Romatoid artrit'li hastalarda etanercept ile yapilan anti-tümör nekroz faktör (TNF)-alfa tedavisinin endotel fonksiyonlari üzerine etkisi]
    (2010) Tikiz H.; Arslan Ö.; Pirildar T.; Tikiz C.; Bayindir P.
    Objective: To investigate the effects of tumor necrosis factor (TNF)-< antagonism with etanercept (ENC) on endothelial functions in patients with active rheumatoid arthritis (RA). Methods: A total of 21 patients with RA were enrolled in this prospective study. Eleven of them (8 women, 3 men mean age 47.0±10.1 years) with high disease activity despite the conventional treatment were assigned to Group 1 and were given ENC treatment twice a week (25 mg SC injection) for 12 weeks. Ten patients with RA (8 women, 2 men mean age 55.0±6.4 years) under conventional methotrexate and prednisone therapy were assigned as Control group (Group 2). Endothelium-dependent and -independent vasodilator responses of the brachial artery were assessed by high-resolution ultrasound. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were also measured at baseline and at the post treatment period. Mann-Whitney U and Wilcoxon tests were used to compare the data and correlation analysis was performed using Pearson correlation test. Results: Endothelium-dependent vasodilatation improved from 5.2±0.8% to 7.9±1.3% (p=0.04) in ENC group, while no significant change was observed in the control group (from 6.6±1.1% to 7.0±1.8% p=0.67). No significant changes were found in endothelium-independent vasodilatation and baseline brachial artery diameters in both groups. A significant reduction in ESR and CRP were observed in patients receiving ENC (from 16.2±6.8 to 9.2± 5.1 mm/h, p=0.003 and from 14.68±3.4 to 9.25± 3.7 mg/L, p=0.003, respectively). Conclusion: Treatment with ENC for 12 weeks significantly improved endothelial function in patients with active RA compared to those under conventional therapy. The findings of the present study support the hypothesis that the use of TNF-< blockers in patients with active RA may reduce the high incidence of cardiovascular complications. (Anadolu Kardiyol Derg 2010; 10: 98-103) © Copyright 2010 by AVES Yayincilik Ltd.
  • Küçük Resim Yok
    Öğe
    The prevalence of microalbuminuria and relevant cardiovascular risk factors in Turkish hypertensive patients
    (2011) Kozan Ö.; Özcan E.E.; Sancaktar O.; Kabakci G.; Sözcüer A.H.; Kerpeten A.; Delice A.; Içli A.; Sökmen A.; Gürlek A.; Abaci A.; Bayram A.; Köşüş A.; Çamsari A.; Sakalli A.; Sert A.; Temizhan A.; Yilmaz A.; Daver A.; Aydinlar A.; Ergin A.; Kiliçoglu A.E.; Birdane A.; Aribaş A.; Lazoglu A.; Özdemir A.; Fiskeci A.; Çelik A.; Bitigen A.; Keskin A.; Yavuz A.; Akyüz A.; Karanfil A.; Ünsal A.; Sinci A.; Gülmez A.U.; Irmak A.; Vural A.; Güven A.; Ilerigelen B.; Erol B.; Polat B.; Tosun B.; Agçal C.; Genç C.; Kirdar C.; Rezzagil C.; Köz C.; Nazli C.; Ceyhan C.; Örem C.; Uyan C.; Türkoglu C.; Gaffari D.; Aytekin D.; Ural D.; Yeşilbursa D.; Aras D.; Semiz E.; Koçak E.; Atalar E.; Varol E.; Onrat E.; Şensoy E.; Acartürk E.; Akarca E.; Aygün E.; Ertaş F.S.; Koca F.; Özmen F.; Ulusoy F.V.; Özerkan F.; Inceer F.K.; Dönmez G.; Topkara G.; Daş G.; Bozkurt H.; Kültürsay H.; Tikiz H.; Akgöz H.; Kaymak H.; Öney H.; Yegin H.; Boga H.; Gök H.; Vural H.; Atasever H.; Arinç H.; Bozdemir H.; Gündüz H.; Tunar H.; Atmaca H.; Dogru I.; Özdogru I.; Susal I.; Kurt I.T.; Dinçer I.; Biyik I.; Tandogan I.; Jordan J.; Kulan K.; Şahna K.; Öztaş K.; Dönmez K.; Övünç K.; Kaya K.; Aytemir K.; Özdemir K.; Tigen K.; Saraç L.; Sirkeci M.T.; Çakmak M.; Şahin M.; Kutlu M.; Bilge M.; Bostan M.; Melek M.; Sunay M.Ö.; Şeker M.; Güçel M.Ş.; Yazici M.; Kayikçioglu M.; Öç M.; Gürsürer M.; Dagalp M.; Bilaloglu M.; Yalçin M.; Şerifi M.; Gökçe M.; Kiliçkap M.; Polat M.; Şan M.; Tahtasiz M.; Yilmaz M.; Etemoglu M.; Coşkun N.; Aran N.S.; Ata N.; Sönmez N.; Çam N.; Koylan N.; Özer N.; Keser N.; Döven O.; Tartanoglu O.; Ergene O.; Elönü O.H.; Onbaşili O.A.; Özbek Ö.; Pinar P.; Akdemir R.; Kargin R.; Topsakal R.; Yoldaş R.; Uçar R.; Ateşal S.; Toktaş S.; Cinsoy S.; Güleç S.; Aytekin S.; Çolak S.; Mecit S.; Sakalli S.; Sevimli S.; Topaloglu S.; Aydogdu S.; Turan S.C.; Kahraman S.; Yorganci S.; Coşkun Ş.; Ünal Ş.; Durmaz T.; Ulusoy T.; Keleş T.; Kirat T.; Gündogdu T.T.; Peker T.; Sümerkan U.; Aytekin V.; Koca V.; Çam V.; Gökçe V.; Gürlertop Y.; Balbay Y.; Çavuşoglu Y.; Erzurum Y.; Selçoki Y.; Yakar Y.; Işilak Z.; Tosun Z.; Kaplan Z.; Tartan Z.
    Objectives: A growing body of data illustrates the importance of microalbuminuria (MAU) as a strong predictor of cardiovascular risk in the hypertensive population. The present study was designed to define the prevalence of MAU and associated cardiovascular risk factors among Turkish hypertensive outpatients. Study design: Representing the Turkish arm of the multinational i-SEARCH study involving 1,750 sites in 26 countries around the world, a total of 1,926 hypertensive patients from different centers were included in this observational and cross-sectional survey study. Patients with reasons for a false-positive MAU test were excluded. The prevalence of MAU was assessed using a dipstick test, and patients were inquired about comorbidities, comedication, and known cardiovascular risk factors. Results: The overall prevalence of MAU was 64.7% and there was no difference between genders. Most of the patients (82.5%) had uncontrolled hypertension, 35.6% had dyslipidemia, and 35.5% had diabetes, predominantly type 2. Almost one-third of the patients (26.4%) had at least one cardiovascular-related comorbidity, with 20.3% having documented coronary artery disease (CAD). Almost all patients (96.8%) had one or more risk factors for cardiovascular disease in addition to hypertension, including family history of myocardial infarction or CAD, diabetes, dyslipidemia, lack of physical exercise, and smoking. A trend towards higher MAU values in the presence of CAD was determined. Conclusion: Microalbuminuria tests should be routinely used as a screening and monitoring tool for the assessment of subsequent cardiovascular morbidity and mortality among hypertensive patients. © 2011 Turkish Society of Cardiology.